10:59 AM EDT, 10/08/2025 (MT Newswires) -- BioVaxys Technology (BIOV.CN) Wednesday said that it has appointed James Tartaglia to its board of directors. He fills a vacancy created by the resignation of Anthony Dutton, who has stepped down.

Tartaglia recently retired as global head of vaccine development and life cycle management for Sanofi. He is also the founder of Tartaglia Consulting.

"We are very excited to have the support of Dr. Tartaglia on the BioVaxys board. We are looking forward to tapping into his expertise as we prioritize DPX-based vaccine programs for fields of significant unmet need and build collaborations with global vaccine companies based on the DPX platform," said chief operating officer Kenneth Kovan.

Biovaxys is down $0.02, to $0.27, on the Canadian Securities Exchange.

Price: 0.26, Change: -0.03, Percent Change: -10.53